ClinicalTrials.gg
Not yet recruitingNCT07770360Updated Aug 18, 2026

Performance Study of the INSTI® and TruPlex Rapid Blood Typing Platforms

An interventional study of INSTI® Rapid Blood Type Test and TruPlex Rapid Blood Type Test in ABO Blood Type and RhD Blood Type, sponsored by bioLytical Laboratories. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by bioLytical Laboratories · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
2,500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

CLS-019A is a prospective, multi-site, parallel clinical performance study. Each enrolled subject is tested on both investigational devices in parallel within a single study visit, yielding paired INSTI® and TruPlex results from matched capillary fingerstick and EDTA-VWB samples.

02

Conditions studied

  • ABO Blood Type
  • RhD Blood Type
03

In context

Lead sponsor

bioLytical Laboratories is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be enrolled in the Main Cohort if they meet all of criteria IC.1 through IC.6. Subjects will be enrolled in the Rare-Phenotype Cohort if they meet all of criteria IC.1 through IC.7:

  1. Subject is 18 years of age or older at the time of enrollment.
  2. Subject is able to provide written prior to any study-related procedures.
  3. Operator or study staff is able to obtain required data to complete the subject's Enrollment Questionnaire.
  4. Subject is able and willing to complete all required study procedures on the allocated testing day.
  5. Subjects is able to speak/read/write in English or Spanish.
  6. Subjects is willing to provide:

    • Two (2) capillary fingerstick whole blood samples, and
    • Venous whole blood samples collected by venipuncture (approximately 10 mL), as required for the study. And
    • If required, a maximum of two (2) further fingerstick whole blood samples in the case that the initial INSTI and/or TruPlex test results are invalid.

    Additional Inclusion Criterion for Rare-Phenotype Cohort Enrollment:

  7. Subject has a previously documented rare ABO subgroup or RhD variant phenotype.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

  1. Subject has known bleeding disorder or any other medical condition that, in the opinion of the Investigator or Operator, contraindicates fingerstick or venipuncture.
  2. Subject has received a blood transfusion within the past 120 days.
  3. Subject is currently using therapeutic anticoagulants (e.g., warfarin, heparin, or direct oral anticoagulants [DOACs]) that, in the opinion of the Investigator or Operator, may interfere with sample collection or test performance.
  4. Subject has any condition which, in the opinion of the Investigator or Operator, would:

    • Place the participant at undue risk,
    • Interfere with completion of study procedures,
    • Compromise the process, or
    • Bias the interpretation of study results. Examples include, but are not limited to: intoxication, acute illness, visible distress, or inability to understand study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Other
    Main Cohort

    Prospectively recruited subjects will undergo testing for ABO and RhD blood type using the INSTI and TruPlex Rapid Blood Typing Tests.

    Diagnostic Test: INSTI® Rapid Blood Type Test · Diagnostic Test: TruPlex Rapid Blood Type Test

  • Other
    Rare Phenotype Cohort

    Subjects with rare blood phenotypes will undergo testing for ABO and RhD blood type using the INSTI and TruPlex Rapid Blood Typing Tests.

    Diagnostic Test: INSTI® Rapid Blood Type Test · Diagnostic Test: TruPlex Rapid Blood Type Test

Interventions

  • Diagnostic testINSTI® Rapid Blood Type Test

    A flow-through blood grouping reagent device intended for the determination of ABO and RhD blood group by forward typing using human whole blood samples.

  • Diagnostic testTruPlex Rapid Blood Type Test

    A lateral-flow blood grouping reagent device intended for the determination of ABO and RhD blood group by forward typing using human whole blood samples.

06

What researchers measure

Primary outcomes

  1. Clinical performance of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood type detection

    To evaluate the clinical performance (PPA and NPA) of the INSTI® and TruPlex Rapid Blood Typing Tests for ABO (A, B, AB, and O) and RhD blood types through detection of A, B, and RhD antigens using both capillary fingerstick and EDTA venous whole blood (VWB) samples. Performance will be determined by comparing the results of each investigational device with reference tests for ABO and RhD status.

    Time frame: 6 months

Secondary outcomes

  1. INSTI® and TruPlex Rapid Blood Typing Test Invalid Rate

    To monitor and report the rate of invalid test results for the INSTI® and TruPlex Rapid Blood Typing Tests.

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Nov 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Aug 18, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Nov 26, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07770360
Responsible party
Sponsor
First posted
Aug 18, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Nov 26, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 18, 2026

Study contacts

Ana Subramanian
Contact
asubramanian@biolytical.com
604-204-6784 ext. 262
Patrick Diaz
Contact
pdiaz@biolytical.com
604-204-6784 ext. 284

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion